Following the publication of the Lilly Q1 2026 Financial Results, Eli Lilly and Company (NYSE: LLY) announced a stellar start to the year, characterized by robust revenue growth and an upward revision of its full-year 2026 financial outlook. Driven by the continued “momentum of new medicines,” particularly in the incretin space, the company has solidified its position as a leader in global healthcare innovation.
Lilly Q1 2026 Financial Results: Key Financial Highlights
The Lilly Q1 2026 Financial Results reflect the successful scaling of manufacturing capacity for tirzepatide-based products. Total revenue saw a significant year-over-year increase, fueled by the commercial success of Zepbound® and Mounjaro®. Consequently, Lilly has raised its full-year 2026 revenue guidance by $2 billion, citing improved supply chain throughput and strong international uptake.
| Metric | Q1 2026 Reported | Q1 2025 Reported | Change (%) |
| Total Revenue | $12.8 Billion | $9.5 Billion | +35% |
| Net Income (GAAP) | $3.1 Billion | $2.2 Billion | +41% |
| Earnings Per Share (EPS) | $3.42 | $2.42 | +41% |
Learn More: Johnson & Johnson Q1 2026 Results: Financial Growth and Pipeline Breakthroughs
Lilly Q1 2026 Financial Results: Comprehensive Product Performance
The core driver of the Lilly Q1 2026 Financial Results was the unparalleled performance of Mounjaro® and Zepbound®. Together, these two treatments generated a combined $12.8 billion in revenue. Mounjaro, specifically, saw its global revenue soar by 125% compared to the previous year, as manufacturing capacity finally began to catch up with global demand.
Key Product Revenue Performance (Q1 2026)
| Product | Q1 2026 Revenue | Q1 2025 Revenue | YoY Change (%) |
| Mounjaro | $8.662 Billion | $3.842 Billion | +125% |
| Zepbound | $4.160 Billion | $2.312 Billion | +80% |
| Jaypirca | $165 Million | $92 Million | +79% |
| Ebglyss | $145 Million | $60 Million | +141% |
| Kisunla | $124 Million | $22 Million | NM* |
| Omvoh | $80 Million | $37 Million | +115% |
| Total Revenue | $19.8 Billion | $12.7 Billion | +56% |
Clinical Pipeline Momentum and Breakthrough Data
Beyond the financial surge, the Lilly Q1 2026 Financial Results highlighted critical advancements in the company’s R&D pipeline. The company continues to invest heavily in its “Triple G” agonist, retatrutide, which is currently in Phase 3 TRIUMPH master studies for obesity and type 2 diabetes (Medpace, 2025).
Additionally, the company showcased impressive data for pirtobrutinib (Jaypirca®) in chronic lymphocytic leukemia (CLL). In a comparative study against ibrutinib, pirtobrutinib demonstrated a superior overall response rate (ORR) in both treatment-naïve and relapsed/refractory populations (Pirtobrutinib Versus Ibrutinib…, 2026).
Learn More: Biogen Q1 2026 Results: Commercial Execution and Pipeline Breakthroughs
Clinical Data Table: Pirtobrutinib vs. Ibrutinib
The following data reflects the efficacy of pirtobrutinib as highlighted in recent clinical reports:
| Patient Group | Pirtobrutinib (ORR %) | Ibrutinib (ORR %) | P-Value |
| Intent-to-Treat (ITT) | 87.0% | 78.5% | .0035 |
| Relapsed/Refractory | 84.0% | 74.8% | .0175 |
| Treatment-Naïve | 92.9% | 85.8% | .0886 |
Kura Oncology and Kyowa Kirin Announce Groundbreaking Kyowa Kirin Ziftomenib Frontline AML Data for EHA 2026 Congress
Kura Oncology and Kyowa Kirin announced updated frontline data for ziftomenib combined with 7+3 chemotherapy in newly diagnosed NPM1-m and KMT2A-r AML patients, demonstrating high […]
GSK and Spero Therapeutics Secure Historic Utebzi FDA Approval for Adults with Complicated Urinary Tract Infections
The historic Utebzi FDA approval introduces the first and only oral carbapenem antibiotic for adult patients suffering from complicated urinary tract infections (cUTIs), offering an […]
Novo Nordisk Cyber Attack: Threat Group Demands $25 Million Ransom Following Massive Data Breach
Following a rejected $25 million extortion attempt, a cybercriminal group claims to have stolen 1.3 terabytes of sensitive data in a sophisticated Novo Nordisk cyber […]
Strategic Growth and Future Outlook
The upward trajectory noted in the Lilly Q1 2026 Financial Results is supported by the company’s commitment to expanding access through platforms like LillyDirect. By integrating telehealth and pharmacy delivery, Lilly is streamlining the patient experience for those seeking treatment for obesity, migraine, and diabetes.
As the U.S. Food and Drug Administration (FDA) continues to review new indications for Lilly’s pipeline, the company remains focused on maintaining its manufacturing lead. With the launch of Kisunla™ (donanemab) for Alzheimer’s disease gaining traction, the remainder of 2026 is expected to see continued margin expansion.
Last Update:
